Contact
Please use this form to send email to PR contact of this press release:
Neurolixis Publishes Positive Phase 2A Trial Results for NLX-112 in Parkinson’s Disease
TO:
ADRIAN NEWMAN-TANCREDI
NEUROLIXIS